title: Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery.
abstract: OBJECTIVE
  To investigate the changes in haemostasis in the three months immediately after stopping the combined contraceptive pill.
  
  
  METHODS
  Prospective randomised study.
  
  
  METHODS
  Family planning centre in London.
  
  
  METHODS
  24 women aged 35-45 investigated before, during, and after six months' use of combined oral contraceptives containing 30 micrograms ethinyl oestradiol together with the progestogens desogestrel or gestodene.
  
  
  RESULTS
  Blood samples were taken immediately before and after six months of oral contraceptive use and one, two, four, six, eight, and 12 weeks after the pill had been stopped. During the six months of oral contraceptive use the plasma concentration of factor X and fibrinogen increased and that of antithrombin III decreased. Between two and six weeks after stopping the pill a rebound phenomenon occurred with plasma concentrations of antithrombin III increasing (mean change from baseline at two weeks 0.06 IU/l and at six weeks 0.10 IU/l) and fibrinogen decreasing (0.26 g/l change at two weeks and 0.40 g/l at six weeks). Factor X concentrations fell gradually and the values at eight weeks were not significantly different from those found before the combined pill was started.
  
  
  CONCLUSIONS
  The combined pill should be stopped at least four weeks before major surgery, which carries the risk of postoperative thrombosis, to allow the potentially prothrombotic haemostatic changes that occur during its use to be corrected.
authors.affiliation: Margaret Pyke Centre, London.
authors.forename: G E
authors.initials: GE
authors.lastname: Robinson
authors.forename: T
authors.initials: T
authors.lastname: Burren
authors.forename: I J
authors.initials: IJ
authors.lastname: Mackie
authors.forename: W
authors.initials: W
authors.lastname: Bounds
authors.forename: K
authors.initials: K
authors.lastname: Walshe
authors.forename: R
authors.initials: R
authors.lastname: Faint
authors.forename: J
authors.initials: J
authors.lastname: Guillebaud
authors.forename: S J
authors.initials: SJ
authors.lastname: Machin
mesh_terms: D000328:Adult; D000990:Antithrombin III / Q000378:metabolism; D003277:Contraceptives, Oral, Combined / Q000494:pharmacology*; D005170:Factor X / Q000378:metabolism; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D013923:Thromboembolism / Q000517:prevention & control*; D013997:Time Factors
chemical_list: D003277:Contraceptives, Oral, Combined; D000990:Antithrombin III; D005170:Factor X; D005340:Fibrinogen